Elizabeth Blair, MD, is a highly regarded surgeon who specializes in head and neck surgery. Dr. Blair is an expert in the diagnosis and treatment of head and neck cancer, thyroid and parathyroid disease, salivary gland tumors and skull base tumors, as well as malignant melanoma and other skin cancers. She has a special interest in treating patients with voice and laryngeal disorders ranging from hoarseness to vocal cord paralysis.
Dr. Blair's research interests include management of laryngeal and voice disorders, functional outcomes of patients treated for head and neck cancer and development of organ preservation therapies for head and neck malignancies. She also has an interest in early diagnosis and prevention of head and neck cancer.
University of Chicago
- Clinical Research Training Program
2004
University of Texas M.D. Anderson Cancer Center
Houston, TX
- Fellow, Advanced Head and Neck Surgical Oncology
1994
University of Pittsburgh
Pittsburgh, PA
- Residency, Otolaryngology-Head and Neck Surgery
1993
Creighton University Affiliated Hospitals
Omaha, NE
- Internship/Residency, General Surgery
1989
Creighton University School of Medicine
Omaha, NE
MD - Doctor of Medicine
1988
Creighton University
Omaha, NE
BS, Cum Laude - Chemistry
1984
Adenoid Cystic Carcinoma with Sebaceous Differentiation and MYB::NFIB Fusion Arising in the External Auditory Canal.
Adenoid Cystic Carcinoma with Sebaceous Differentiation and MYB::NFIB Fusion Arising in the External Auditory Canal. Head Neck Pathol. 2024 Sep 23; 18(1):85.
PMID: 39312083
Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab.
Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab. Cancer Gene Ther. 2024 Oct; 31(10):1477-1485.
PMID: 39085630
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
PMID: 38842838
Imaging features and surgical management of giant parathyroid adenoma with autoinfarction.
Imaging features and surgical management of giant parathyroid adenoma with autoinfarction. J Clin Imaging Sci. 2024; 14:9.
PMID: 38628608
Regional distribution in female representation in US otolaryngology faculty.
Regional distribution in female representation in US otolaryngology faculty. Laryngoscope Investig Otolaryngol. 2023 Aug; 8(4):832-838.
PMID: 37621283
Advice and perspectives from navigating the couples match in otolaryngology: A qualitative pilot study.
Advice and perspectives from navigating the couples match in otolaryngology: A qualitative pilot study. Laryngoscope Investig Otolaryngol. 2023 Jun; 8(3):693-698.
PMID: 37342108
Practice patterns for initial management of oral leukoplakia amongst otolaryngologists and oral and maxillofacial surgeons.
Practice patterns for initial management of oral leukoplakia amongst otolaryngologists and oral and maxillofacial surgeons. Oral Oncol. 2023 04; 139:106341.
PMID: 36842197
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023 02 18; 76(4):720-729.
PMID: 35235656
Laryngeal and pharyngeal actinomycosis: a systematic review and report of 3 cases.
Laryngeal and pharyngeal actinomycosis: a systematic review and report of 3 cases. Am J Otolaryngol. 2022 Nov-Dec; 43(6):103609.
PMID: 36029619
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
PMID: 35945244
Exceptional Women in Medicine, Top Doctor
Castle and Connolly
2017 - 2021
Making a Difference Award, Distinguished Hospital Service
University of Chicago Medicine Hospitals
2015
Distinguished Service Honor Award
American Academy of Otolaryngology-Head and Neck Surgery Foundation
2013
Top Doctors, Otolaryngology
Chicago Magazine
2012 - 2021
America’s Top Doctor for Cancer
Castle and Connolly
2012 - 2021
Alpha Omega Alpha, Alumni Award
Creighton University School of Medicine
2009
Best Poster Presentation
AAOHNS Annual Meeting
2004
Best Paper, Young Surgical Educators
Society of University Otolaryngologists
1998
Honor Award
American Academy of Otolaryngology-Head and Neck Surgery Foundation
1998
Meritorious Service Medal
US Army
1998
Army Commendation Medal
US Army
1997
Army Achievement Medal
US Army
1995 - 1996